sar425899 dual agonist glp-1 glucagon sanofi in type 2 diabetes: Friend or foe? - Caruso - 2023 - Diabetes/Metabolism Research and Reviews The Road towards Triple Agonists:

This multi-dimensional therapeutic potential is reshaping the positioning of GLP-1 drugs as comprehensive metabolic treatments rather than just glucose-lowering agents For instance, Novo Nordisks semaglutide is now marketed as Wegovy specifically for chronic weight management, while Eli Lillys tirzepatide has received FDA approval under the brand name Zepbound for obesity treatment, independent of diabetic status

And growing each & every day by proving its worth with undeniable results

Whats clear is that individual response varies widely, reinforcing the need for personalization

Lower GPX4 levels trigger oxidative damage and cell toxicity, resulting in reduced corneal epithelial cell survival and impaired wound healing ability

10.1158/1535-7163.MCT-08-1072 Mol

Van Gaal L, Souhami E, Zhou T, Aronson R